From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities

Seminars in Radiation Oncology

Volumn 18, Issue 2, 2008, Pages 75-88

  Bentzen, Søren M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER STEM CELL; CLINICAL TRIAL; CYTOLOGY; DISEASE COURSE; DNA DAMAGE; DNA MICROARRAY; GENE FREQUENCY; HEAD AND NECK CARCINOMA; HORMONE RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MICROARRAY ANALYSIS; NONHUMAN; ONCOGENE NEU; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION HAZARD; RADIATION INJURY; RADIATION RESPONSE; RADIATION SAFETY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN FIBROBLAST; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

HUMANS; NEOPLASMS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION ONCOLOGY; RADIOBIOLOGY; TECHNOLOGY, RADIOLOGIC;

EID: 39749178409     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.10.003     Document Type: Article

References (108)

1. Bentzen S.M. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 6 (2006) 702-713
2. Kolch W., Mischak H., and Pitt A.R. The molecular make-up of a tumour: Proteomics in cancer research. Clin Sci (Lond) 108 (2005) 369-383
3. Sakaki Y., Kholodenko B.N., Hatakeyama M., et al. The International Consortium on Systems Biology of Receptor Tyrosine Kinase Regulatory Networks. IEE Proc Syst Biol 152 (2005) 53-54
4. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
5. Bentzen S.M. Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 77 (2005) 227-230
6. Bentzen S.M. High-tech in radiation oncology: Should there be a ceiling?. Int J Radiat Oncol Biol Phys 58 (2004) 320-330
7. Bentzen S.M. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
8. Munro T.R., and Gilbert C.W. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br J Radiol 34 (1961) 246-251
9. Thames H.D., and Hendry J.H. Fractionation in Radiotherapy (1987), Taylor & Francis, London 1-1
10. Fertil B., and Malaise E.P. Inherent radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 7 (1981) 621-629
11. West C.M.L., Davidson S.E., Hendry J.H., et al. Prediction of cervical carcinoma response to radiotherapy. Lancet 338 (1991) 818
12. Begg A.C., Haustermans K., Hart A.A., et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis. Radiother Oncol 50 (1999) 13-23
13. Burnet N.G., Nyman J., Turesson I., et al. Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity. Lancet 339 (1992) 1570-1571
14. Geara F.B., Peters L.J., Ang K.K., et al. Prospective comparison of in vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 27 (1993) 1173-1179
15. Johansen J., Bentzen S.M., Overgaard J., et al. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol 40 (1996) 101-109
16. Johansen J., Bentzen S.M., Overgaard J., et al. Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int J Radiat Biol 66 (1994) 407-412
17. Brock W.A., Tucker S.L., Geara F.B., et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 32 (1995) 1371-1379
18. Russell N.S., Grummels A., Hart A.A., et al. Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer. Int J Radiat Biol 73 (1998) 661-670
19. Peacock J., Ashton A., Bliss J., et al. Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol 55 (2000) 173-178
20. Nordsmark M., Bentzen S.M., and Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. Acta Oncol 33 (1994) 383-389
21. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
22. Nordsmark M., and Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57 (2000) 39-43
23. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
24. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
25. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
26. Moeller B.J., Dreher M.R., Rabbani Z.N., et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
27. Ataman O.U., Bentzen S.M., Saunders M.I., et al. Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis. Br J Cancer 85 (2001) 1113-1118
28. Ataman O.U., Bentzen S.M., Wilson G.D., et al. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 40 (2004) 2734-2741
29. Schechter A.L., Hung M.C., Vaidyanathan L., et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229 (1985) 976-978
30. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
31. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
32. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
33. Chien K.R. Herceptin and the heart-A molecular modifier of cardiac failure. N Engl J Med 354 (2006) 789-790
34. Vaupel P., Thews O., and Hoeckel M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 18 (2001) 243-259
35. Crawford J. Erythropoietin: High profile, high scrutiny. J Clin Oncol 25 (2007) 1021-1023
36. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
37. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
38. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23 (2005) 5960-5972
39. Goldberg P. Danish researchers post long-awaited Aranesp results-Ever so discreetly. The Cancer Letter 33 (2007) 1-7
40. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
41. Deeken J.F., Figg W.D., Bates S.E., et al. Toward individualized treatment: Prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 18 (2007) 111-126
42. Sugiyama E., Kaniwa N., Kim S.R., et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol 25 (2007) 32-42
43. Overgaard J., Eriksen J.G., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
44. Buffa F.M., Bentzen S.M., Daley F.M., et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 10 (2004) 3745-3754
45. Harari P.M., and Huang S.M. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49 (2001) 427-433
46. Schmidt-Ullrich R.K., Contessa J.N., Lammering G., et al. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22 (2003) 5855-5865
47. Bentzen S.M. Repopulation in radiation oncology: Perspectives of clinical research. Int J Radiat Biol 79 (2003) 581-585
48. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23 (2005) 5560-5567
49. Eriksen J.G., Steiniche T., Askaa J., et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58 (2004) 561-566
50. Eriksen J.G., Steiniche T., and Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinoma of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 74 (2005) 93-100
51. Dische S., Saunders M.I., Barrett A., et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44 (1997) 123-136
52. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
53. Atkins D., Reiffen K.A., Tegtmeier C.L., et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52 (2004) 893-901
54. Chua D.T., Nicholls J.M., Sham J.S., et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 11-20
55. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
56. van't Veer L., Dai H., van d V., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
57. Abdullah-Sayani A., Bueno-de-Mesquita J.M., and van de Vijver M. Technology Insight: Tuning into the genetic orchestra using microarrays-Limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol 3 (2006) 501-516
58. van de Vijver M., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
59. Buyse M., Loi S., van't V.L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
60. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
61. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 (2007) 3207-3214
62. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006) 560-569
63. Michiels S., Koscielny S., and Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 365 (2005) 488-492
64. Eden P., Ritz C., Rose C., et al. "Good old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40 (2004) 1837-1841
65. Dunkler D., Michiels S., and Schemper M. Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer 43 (2007) 745-751
66. Michiels S., Koscielny S., and Hill C. Interpretation of microarray data in cancer. Br J Cancer 96 (2007) 1155-1158
67. Benjamin Y., and Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B 57 (2007) 289-300
68. Bentzen S.M. Prognostic factor studies in oncology. Int J Radiat Oncol Biol Phys 49 (2001) 513-518
69. Pawitan Y., Michiels S., Koscielny S., et al. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21 (2005) 3017-3024
70. Sargent D.J., Conley B.A., Allegra C., et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23 (2005) 2020-2027
71. Bogaerts J., Cardoso F., Buyse M., et al. Gene signature evaluation as a prognostic tool: Challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3 (2006) 540-551
72. Trott K.R. Tumour stem cells: The biological concept and its application in cancer treatment. Radiother Oncol 30 (1994) 1-5
73. Denekamp J. Tumour stem cells: Facts, interpretation and consequences. Radiother Oncol 30 (1994) 6-10
74. Dirks P.B. Cancer: Stem cells and brain tumours. Nature 444 (2006) 687-688
75. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
76. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
77. Krause M., Prager J., Zhou X., et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol 83 (2007) 316-325
78. Safwat A., Bentzen S.M., Turesson I., et al. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 52 (2002) 198-204
79. Bentzen S.M., Dorr W., Anscher M.S., et al. Normal tissue effects: Reporting and analysis. Semin Radiat Oncol 13 (2003) 189-202
80. Trotti A., and Bentzen S.M. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22 (2004) 19-22
81. Bentzen S.M., and Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal-tissue injury. Semin Radiat Oncol 4 (1994) 68-80
82. Holscher T., Bentzen S.M., and Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. Radiother Oncol 78 (2006) 123-130
83. Bentzen S.M., Overgaard M., and Thames H.D. Fractionation sensitivity of a functional endpoint: Impaired shoulder movement after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 17 (1989) 531-537
84. Honore H.B., Bentzen S.M., Moller K., et al. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: Individualized risk estimation. Radiother Oncol 65 (2002) 9-16
85. Kruglyak L., and Nickerson D.A. Variation is the spice of life. Nat Genet 27 (2001) 234-236
86. Hinds D.A., Stuve L.L., Nilsen G.B., et al. Whole-genome patterns of common DNA variation in three human populations. Science 307 (2005) 1072-1079
87. Houlston R.S., and Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene 23 (2004) 6471-6476
88. Imyanitov E.N., Togo A.V., and Hanson K.P. Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett 204 (2004) 3-14
89. Ross J.S., Schenkein D.P., Kashala O., et al. Pharmacogenomics. Adv Anat Pathol 11 (2004) 211-220
90. Andreassen C.N. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?. Acta Oncol 44 (2005) 801-815
91. Bahlo M., Stankovich J., Speed T.P., et al. Detecting genome wide haplotype sharing using SNP or microsatellite haplotype data. Hum Genet 119 (2006) 38-50
92. Hirschhorn J.N., and Daly M.J. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6 (2005) 95-108
93. Wang W.Y., Barratt B.J., Clayton D.G., et al. Genome-wide association studies: Theoretical and practical concerns. Nat Rev Genet 6 (2005) 109-118
94. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678
95. Easton D.F., Pooley K.A., Dunning A.M., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 (2007) 1087-1093
96. West C.M., McKay M.J., Holscher T., et al. Molecular markers predicting radiotherapy response: Report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 62 (2005) 1264-1273
97. Ho A.Y., Atencio D.P., Peters S., et al. Genetic predictors of adverse radiotherapy effects: The Gene-PARE project. Int J Radiat Oncol Biol Phys 65 (2006) 646-655
98. Burnet N.G., Elliott R.M., Dunning A., et al. Radiosensitivity, radiogenomics and RAPPER. Clin Oncol (R Coll Radiol) 18 (2006) 525-528
99. Andreassen C.N., Alsner J., Overgaard M., et al. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69 (2003) 127-135
100. Andreassen C.N., Alsner J., Overgaard M., et al. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1. SOD2, XRCC1, XRCC3, APEX and ATM-A study based on DNA from formalin fixed paraffin embedded tissue samples Int J Radiat Biol 82 (2006) 577-586
101. Quarmby S., Fakhoury H., Levine E., et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 79 (2003) 137-143
102. Giotopoulos G., Symonds R.P., Foweraker K., et al. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 96 (2007) 1001-1007
103. Andreassen C.N., Alsner J., Overgaard J., et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75 (2005) 18-21
104. Andreassen C.N., Overgaard J., Alsner J., et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 64 (2006) 776-783
105. Damaraju S., Murray D., Dufour J., et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12 (2006) 2545-2554
106. Moher D., Jones A., and Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-and-after evaluation. JAMA 285 (2001) 1992-1995
107. Bentzen S.M. Towards evidence based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol 46 (1998) 5-18
108. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies. (REMARK). J Natl Cancer Inst 97 (2005) 1180-1184